BiotechTube

Autogene Cevumeran + Nivolumab + Saline

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Muscle-invasive Urothelial Carcinoma

Conditions

Muscle-invasive Urothelial Carcinoma

Trial Timeline

Dec 9, 2024 → Jan 6, 2034

NCT ID
NCT06534983

About Autogene Cevumeran + Nivolumab + Saline

Autogene Cevumeran + Nivolumab + Saline is a phase 2 stage product being developed by Roche for Muscle-invasive Urothelial Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06534983. Target conditions include Muscle-invasive Urothelial Carcinoma.

What happened to similar drugs?

0 of 3 similar drugs in Muscle-invasive Urothelial Carcinoma were approved

Approved (0) Terminated (0) Active (3)
🔄Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
🔄Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3
🔄AtezolizumabRochePhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06534983Phase 2Recruiting

Competing Products

12 competing products in Muscle-invasive Urothelial Carcinoma

See all competitors
ProductCompanyStageHype Score
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
44
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3
44
Durvalumab (Imfinzi) + TremelimumabAstraZenecaPhase 2
27
Pembrolizumab + GemcitabineMerckPhase 2
39
Chemotherapy + Immunotherapy Induction + Immunotherapy MaintenanceMerckPhase 2
42
AtezolizumabRochePhase 3
44
Nivolumab + Nab-paclitaxel + NivolumabBristol Myers SquibbPhase 2
31
Cretostimogene GrenadenorepvecCG OncologyPhase 2
39
CG0070 + NivolumabCG OncologyPhase 1
26
AU-011Aura BiosciencesPhase 1
26
REOLYSIN® + Gemcitabine + CisplatinOncolytics BiotechPhase 1
11